Cellular therapy injections in today's orthopedic market: A social media analysis

Ramkumar, Prem N.; Navarro, Sergio M.; Haeberle, Heather S.; Chughtai, Morad; Demetriades, Christopher; Piuzzi, Nicolás S.; Mont, Michael A.; Bauer, Thomas W.; Muschler, George F.

doi:10.1016/j.jcyt.2017.08.006

Cited by 23 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the lack of substantial evidence supporting the use of "stem cell" injections for knee OA, there is no insurance coverage for such injections, and patients must pay for expenses out-of-pocket [11]. This has led to the rise in direct-to-consumer marketing by clinics that offer these cell therapies [12], with marked outreach by clinics and healthcare providers offering them to patients online and over social media [13].…”

mentioning

confidence: 99%

Analysis of Readability, Quality, and Content of Online Information Available for “Stem Cell” Injections for Knee Osteoarthritis

Mont

Piuzzi

2020

The Journal of Arthroplasty

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Analysis of Readability, Quality, and Content of Online Information Available for “Stem Cell” Injections for Knee Osteoarthritis

Mont

Piuzzi

2020

The Journal of Arthroplasty

Self Cite

View full text Add to dashboard Cite

“…23,32,33 Two potential targets for these injections are BMLs associated with "bottom-up" sub-chondral disease and/or the intraarticular space which may play a role in mediating classic "top-down" knee OA. [33][34][35][36][37] The general principle of biologic therapies is to augment the role of growth factors on tissue maintenance and repair, though their specific mechanism of action may vary according to the specific agent, its site of delivery, method of formulation, and other factors. 23 The role of platelet-rich plasma (PRP) in treatment of knee OA remains an active area of biotherapeutic research.…”

mentioning

confidence: 99%

Are Subchondral Intraosseous Injections Effective and Safe for the Treatment of Knee Osteoarthritis? A Systematic Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

Knee osteoarthritis (OA) is a highly prevalent disease and treatment options for early stages of OA are needed. Intraosseous injections of bone substitute and biologic materials have been proposed to expand the therapeutic arsenal by potentially halting OA progression and delaying the need for knee arthroplasty in patients with early/moderate-stage disease. Therefore, the goal of this study was assessed the efficacy and safety of subchondral intraosseous injection for the treatment of knee OA. A systematic review was performed on PubMed-Medline, and the Cochrane Database of systematic reviews. English and Spanish retrospective and prospective studies assessing the results of subchondral intraosseous injection of bone substitute materials and/or biologicals in human patients with knee OA, with a minimum of 6 months of follow-up were collected. A total of 1,081 potential articles were identified through our search. Six studies were included with a total of 163 patients. The mean follow-up was 18 months (range: 6–24 months). Patient reported outcomes measures (PROMs), complications, and conversion to total knee arthroplasty (TKA) were collected. All six studies showed PROMs improvement relative to baseline. Overall, the five studies reporting visual-analog scale (VAS) pain outcomes improved from a baseline mean score of 6.68 to 2.74. Also, knee injury and osteoarthritis score (KOOS), Tegner-Lysholm, and/or international knee documentation committee (IKDC) scores rose compared with baseline scores in all studies. Overall, 2.5% (4/163) of patients had a complication attributed to study-related treatment. Most patients (81%, 86/106) remained TKA-free at a 1-year follow-up. Subchondral intraosseous injections of bone substitute materials and platelet-rich plasma (PRP) suggest (1) improved PROMs of pain and functional status, (2) low complication rate, and (3) relatively low rates of conversion to TKA. However, the current studies investigating these treatments exhibited high degree of heterogeneity in both measurement of outcomes and delivery of treatment, with a high risk of bias. This procedure should not be utilized in advanced knee OA. In light of the limitations of the current literature, advising in favor or against this therapy for early to moderate knee OA is challenging.

show abstract

“…Another report examined messaging related to cell-based therapies for musculoskeletal conditions on social media and found that these messages were dominated by businesses that portray an almost exclusively positive tone, without providing a "fair balance" on the risks, benefits and limitations, reflecting an environment of hype that contributes to public misunderstanding related to the extent to which efficacy has been documented [16].…”

Section: Provenàunproven Therapies Massimo Dominici MDmentioning

confidence: 99%

Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cellular therapy injections in today's orthopedic market: A social media analysis

Cited by 23 publications

References 26 publications

Analysis of Readability, Quality, and Content of Online Information Available for “Stem Cell” Injections for Knee Osteoarthritis

Analysis of Readability, Quality, and Content of Online Information Available for “Stem Cell” Injections for Knee Osteoarthritis

Are Subchondral Intraosseous Injections Effective and Safe for the Treatment of Knee Osteoarthritis? A Systematic Review

Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies—promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018

Contact Info

Product

Resources

About